KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE).

Esther Natalie Oliva, Anna Candoni, Prassede Salutari, Giuseppe A Palumbo, Gianluigi Reda, Giuseppe Iannì, Giovanni Tripepi, Maria Cuzzola, Debora Capelli, Corrado Mammì, Caterina Alati, Maria Concetta Cannatà, Pasquale Niscola, Bianca Serio, Pellegrino Musto, Ernesto Vigna, Antonio Volpe, Lorella Maria Antonia Melillo, Maria Teresa Arcadi, Donato Mannina, Maria Elena Zannier, Roberto Latagliata

Cancers (Basel) 15(9) 2441

PMID37173908
PMCIDPMC10177242
DOI10.3390/cancers15092441
发表日期2023-05-13
摘要

摘要

This phase-3 randomized multicenter trial evaluated the efficacy of subcutaneous azacitidine (AZA) post-remission therapy vs. best supportive care (BSC) in elderly acute myeloid leukemia (AML) patients. The primary endpoint was the difference in disease-free survival (DFS) from complete remission (CR) to relapse/death. Patients with newly diagnosed AML aged ≥61 years received two courses of induction chemotherapy ("3+7" daunorubicin and cytarabine) followed by consolidation (cytarabine). At CR, 54 patients were randomized (1:1) to receive BSC (N = 27) or AZA (N = 27) at a dose of 50 mg/m2 for 7 days every 28 days and the dose increased after the 1st cycle to 75 mg/m2 for a further 5 cycles, followed by cycles every 56 days for 4.5 years. At 2 years, median DFS was 6.0 (95% CI: 0.2-11.7) months for patients receiving BSC vs. 10.8 months (95% CI: 1.9-19.6, p = 0.20) months for AZA. At 5 years, DFS was 6.0 (95% CI: 0.2-11.7) months in the BSC arm vs. 10.8 (95% CI: 1.9-19.6, p = 0.23) months in the AZA arm. Significant benefit was afforded by AZA on DFS at 2 and 5 years in patients aged >68 years (HR = 0.34, 95% CI: 0.13-0.90, p = 0.030 and HR = 0.37, 95% CI: 0.15-0.93, p = 0.034, respectively). No deaths occurred prior to leukemic relapse. Neutropenia was the most frequent adverse event. There were no differences in patient-reported outcome measures between study arms. In conclusion, AZA post-remission therapy was found to provide benefit in AML patients aged >68 years.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。